Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis

被引:36
|
作者
Medipally, Dinesh K. R. [1 ,2 ]
Cullen, Daniel [1 ,2 ]
Untereiner, Valerie [3 ,4 ]
Sockalingum, Ganesh D. [3 ]
Maguire, Adrian [1 ,2 ]
Thi Nguyet Que Nguyen [1 ,2 ]
Bryant, Jane [2 ]
Noone, Emma [5 ]
Bradshaw, Shirley [5 ]
Finn, Marie [5 ]
Dunne, Mary [5 ]
Shannon, Aoife M. [6 ]
Armstrong, John [7 ]
Meade, Aidan D. [1 ,2 ]
Lyng, Fiona M. [1 ,2 ]
机构
[1] Technol Univ Dublin, Sch Phys & Clin & Optometr Sci, Kevin St, Dublin D08 NF82, Ireland
[2] Technol Univ Dublin, Radiat & Environm Sci Ctr, Focas Res Inst, Dublin D08 NF82, Ireland
[3] Univ Reims, BioSpecT EA 7506, UFR Pharm, Reims, France
[4] Univ Reims, PICT, Reims, France
[5] St Lukes Hosp, St Lukes Radiat Oncol Network, Clin Trials Unit, Dublin, Ireland
[6] Canc Trials Ireland, Dublin, Ireland
[7] St Lukes Hosp, St Lukes Radiat Oncol Network, Dept Radiat Oncol, Dublin, Ireland
基金
爱尔兰科学基金会;
关键词
FTIR spectroscopy; liquid biopsy; partial least squares discriminant analysis and classical least squares fitting analysis; principal component analysis; prostate cancer; Raman spectroscopy; RAMAN-SPECTROSCOPY; INFRARED-SPECTROSCOPY; SERUM CREATININE; NUCLEIC-ACIDS; IN-VITRO; PLASMA; CELLS; RISK; IDENTIFICATION; BIOMARKERS;
D O I
10.1177/1758835920918499
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Screening for prostate cancer with prostate specific antigen and digital rectal examination allows early diagnosis of prostate malignancy but has been associated with poor sensitivity and specificity. There is also a considerable risk of over-diagnosis and over-treatment, which highlights the need for better tools for diagnosis of prostate cancer. This study investigates the potential of high throughput Raman and Fourier Transform Infrared (FTIR) spectroscopy of liquid biopsies for rapid and accurate diagnosis of prostate cancer. Methods: Blood samples (plasma and lymphocytes) were obtained from healthy control subjects and prostate cancer patients. FTIR and Raman spectra were recorded from plasma samples, while Raman spectra were recorded from the lymphocytes. The acquired spectral data was analysed with various multivariate statistical methods, principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and classical least squares (CLS) fitting analysis. Results: Discrimination was observed between the infrared and Raman spectra of plasma and lymphocytes from healthy donors and prostate cancer patients using PCA. In addition, plasma and lymphocytes displayed differentiating signatures in patients exhibiting different Gleason scores. A PLS-DA model was able to discriminate these groups with sensitivity and specificity rates ranging from 90% to 99%. CLS fitting analysis identified key analytes that are involved in the development and progression of prostate cancer. Conclusions: This technology may have potential as an alternative first stage diagnostic triage for prostate cancer. This technology can be easily adaptable to many other bodily fluids and could be useful for translation of liquid biopsy-based diagnostics into the clinic.
引用
收藏
页数:23
相关论文
共 50 条
  • [22] Prostate cancer diagnosis in patients undergoing two extended biopsies
    Vakar-Lopez, F
    Naya, Y
    Okihara, K
    Mian, B
    Chen, ME
    Babaian, RJ
    Troncoso, P
    LABORATORY INVESTIGATION, 2002, 82 (01) : 185A - 185A
  • [23] Clinical utility of emerging biomarkers in prostate cancer liquid biopsies
    Boerrigter, Emmy
    Groen, Levi N.
    Van Erp, Nielka P.
    Verhaegh, Gerald W.
    Schalken, Jack A.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2020, 20 (02) : 219 - 230
  • [24] Diagnosis of prostate cancer in needle biopsies after radiation therapy
    Cheng, L
    Cheville, JC
    Bostwick, DG
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (10) : 1173 - 1183
  • [25] Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer
    Tulpule, Varsha
    Morrison, Gareth J.
    Falcone, Mary
    Quinn, David I.
    Goldkorn, Amir
    CURRENT ONCOLOGY REPORTS, 2022, 24 (10) : 1287 - 1298
  • [26] Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer
    Valentino, A.
    Reclusa, P.
    Sirera, R.
    Giallombardo, M.
    Camps, C.
    Pauwels, P.
    Crispi, S.
    Rolfo, C.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 651 - 657
  • [27] Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer
    Varsha Tulpule
    Gareth J. Morrison
    Mary Falcone
    David I. Quinn
    Amir Goldkorn
    Current Oncology Reports, 2022, 24 : 1287 - 1298
  • [28] Current status of liquid biopsies for the detection and management of prostate cancer
    Lu, Yi-Tsung
    Delijani, Kevin
    Mecum, Andrew
    Goldkorn, Amir
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 5271 - 5291
  • [29] Interrogating the AR in advanced prostate cancer using liquid biopsies
    Antonarakis, E.
    CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (03) : 178 - 178
  • [30] Current advances of liquid biopsies in prostate cancer: Molecular biomarkers
    Alahdal, Murad
    Perera, Roshane A.
    Moschovas, Marcio Covas
    Patel, Vipul
    Perera, Ranjan J.
    MOLECULAR THERAPY ONCOLYTICS, 2023, 30 : 27 - 38